Business
Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indications for Its Proprietary eyonis®...
SOPHIA ANTIPOLIS, France, May 27, 2026--Regulatory News: Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indications for Its Proprietary eyonis® Pan-Cancer Early Diagnostics Suite
About this update from Median Technologies
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1240,"height":461,"url":"https://media.zenfs.com/en/business-wire.com/631ba7b50cbf39346064e63c20ffcea0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.UqrXpG3X9PTqwE89L9wQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1Nw--/https://media.zenfs.com/en/business-wire.com/631ba7b50cbf39346064e63c20ffcea0","width":960,"height":357},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/p2OXOynpN6igk4xElgQPng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIzOA--/https://media.zenfs.com/en/business-wire.com/631ba7b50cbf39346064e63c20ffcea0","width":640,"height":238},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/XPwv42dDSPmIfJz0SDDfvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04OTI-/https://media.zenfs.com/en/business-wire.com/631ba7b50cbf39346064e63c20ffcea0","width":1200,"height":446}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Share capital increase without shareholders’ preferential subscription rights, to be carried out by way of an issue of ordinary shares in the framework of a public offering, for an amount of approximately 40 million euros.","length":222,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"A share capital increase without shareholders’ preferential subscription rights reserved for the Guarantors (as defined below) for a maximum amount of 10 million euros, should all the ordinary shares issued in the framework of the public offering be fully subscribed;","length":267,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Firm subscription and backstop commitments for a total amount of 30 million euros, including 20 million euros under the subscription commitments, representing total commitments equal to 75% of the public offering;","length":213,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Subscription price: 5.00 euros per ordinary share; and","length":54,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The net proceeds of the share capital increase will be allocated to the commercial launch of eyonis® LCS in the United States and Europe, and to the financing of the extension of the eyonis® medical device software suite for the early diagnosis of cancers through imaging.","length":272,"tagName":"p","attribs":{}}]}],...